Introduction Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Recent years have …

Simple Summary The progress of next-generation sequencing technologies has raised
huge expectations for precision-medicine therapy approaches in breast cancer and triple …

Breast cancer (BC), one of the most widespread and devastating diseases affecting women
worldwide, presents a significant public health challenge. This review explores the emerging …

Background: Breast cancer is the most common form of cancer in women worldwide.
Advances in the early diagnosis and treatment of cancer in the last decade have …

Neoadjuvant chemotherapy (NACT) has become the standard of care for high‐risk breast
cancer, including triple‐negative (TNBC) and HER2‐positive disease. As a result, handling …

Dear Editor, Pembrolizumab, an immune checkpoint inhibitor (ICI), was recently approved
for early-stage triple-negative breast cancer (eTNBC), and promising results have been …

Immune checkpoint inhibitors (ICIs) have a modest clinical activity when administered as
monotherapy against breast cancer (BC), the most common malignancy in women. Novel …

Breast cancer (BC) continues to be the most diagnosed tumor in women and a very
heterogeneous disease both inter-and intratumoral, mainly given by the variety of molecular …

Immunotherapy has emerged as a revolutionary approach in cancer therapy, and recent
advancements hold significant promise for breast cancer (BCa) management. Employing the …

Breast cancer poses one of the largest threats to women's health. Treatment continues to
improve for all the subtypes of breast cancer, but some subtypes, such as triple negative …